abrdn Income Credit Strategies Fund vs Recursion Pharmaceuticals Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.11 (market cap $641.16M), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.8× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ACP | RXRX | |
|---|---|---|
Market Cap | $641.16M | $1.81B |
Sector | Financials | Health |
52-Week High | $5.98 | $6.79 |
52-Week Low | $5.01 | $2.84 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $1.33B |
Trailing returns across standard periods
Latest headlines on both assets
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →